Adjuvant Gefitinib Extended Disease-Free Survival in Patients With Stage II/IIIA Non-Small Cell Lung Cancer With EGFR-Activating Mutations

Breaking News Briefs

Frances A. Shepherd, OC, OOnt, MD, FRCPC

Raymond Osarogiagbon, MBBS, FACP

IASLC 18th World Conference on Lung Cancer

ADJUVANT Trial of Gefitinib Versus Chemotherapy in Resected EGFR-Mutations Non-Small Cell Lung Cancer

IASLC Leader Elected President of ESMO for 2020–2021: Solange Peters, MD, PhD

PJ Souquet, MD

Ellen V. Sigal, PhD: Leading the Cancer Research Advocacy Community

Breaking News Briefs

NCI Corner - Interview with Jeff Abrams

Suicide and Lung Cancer: Screening Is Only the First Step